Thalidomide

Generic Name: Thalidomide

Brand Names: Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₀N_₂O_₄

CAS Number: 50-35-1

Unique Ingredient Identifier: 4Z8R6ORS6L

Background: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...

Indication: Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions: Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Phase 2

Not yet recruiting

Conditions: Radiation Enteritis

Interventions: Drug: Thalidomide
Drug: Glutamine
Drug: Thalidomide+Glutamine

First Posted Date: 2024-09-27

Last Posted Date: 2024-10-01

Lead Sponsor: Yongquan Shi

Target Recruit Count: 150

Registration Number: NCT06617182

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Phase 2

Recruiting

Conditions: Fetal Hemoglobin
Genetic Disease
Thalassemia Major

Interventions: Drug: Thalidomide

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-12

Lead Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Target Recruit Count: 54

Registration Number: NCT06490627

Locations: 🇵🇰
National Institute of blood disease and bone marrow transplant, Karachi, Sindh, Pakistan

Long Term Beta Thalassemia Treatment: Findings From The Extension Period

Phase 2

Active, not recruiting

Conditions: Beta-Thalassemia
Hemoglobinopathies
Fetal Hemoglobin

Interventions: Drug: thalidomide and hydroxyurea
Drug: Thalidomide

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Target Recruit Count: 30

Registration Number: NCT06490601

Locations: 🇵🇰
National Institute of blood disease and bone marrow transplant, Karachi, Sindh, Pakistan

Thalidomide Therapy for VEOIBD

Recruiting

Conditions: Inflammatory Bowel Diseases

First Posted Date: 2024-04-24

Last Posted Date: 2024-07-03

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 40

Registration Number: NCT06382519

Locations: 🇨🇳
Lin Wang, Shanghai, Shanghai, China

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Phase 4

Recruiting

Conditions: Transfusion-dependent Thalassemia

Interventions: Drug: Hydroxy Urea
Drug: Combinations
Drug: Thalidomide

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 90

Registration Number: NCT06299670

Locations: 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

The Therapeutic Effect of Thalidomide in Syringomyelia

Phase 2

Recruiting

Conditions: Syringomyelia
Thalidomide

Interventions: Drug: Thalidomide

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Xuanwu Hospital, Beijing

Target Recruit Count: 30

Registration Number: NCT06268093

Locations: 🇨🇳
Fengzeng Jian, Beijing, Beijing City, China

Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients

Phase 3

Completed

Conditions: Transfusion-dependent Beta-Thalassemia

Interventions: Drug: Thalidomide

First Posted Date: 2023-11-24

Last Posted Date: 2023-11-24

Lead Sponsor: Blood Care Clinic

Target Recruit Count: 200

Registration Number: NCT06146478

Locations: 🇵🇰
Blood Care Clinic, Peshawar, Khyber Pakhtunkhwa, Pakistan

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Phase 3

Recruiting

Conditions: Pancreatic Cancer Stage IV
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Thalidomide
Drug: Nab paclitaxel
Drug: Placebo
Drug: Gemcitabine

First Posted Date: 2023-08-30

Last Posted Date: 2023-11-24

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06017284

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

Phase 4

Conditions: Thalidomide
Haemodialysis
Uremic Pruritus

Interventions: Drug: Placebo
Drug: Thalidomide

First Posted Date: 2022-09-01

Last Posted Date: 2022-09-01

Lead Sponsor: RenJi Hospital

Target Recruit Count: 40

Registration Number: NCT05525234

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Thalidomide
Drug: TAS-102

First Posted Date: 2022-03-04

Last Posted Date: 2022-03-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT05266820

Locations: 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳
Fuzhou First Hospital affiliated to Fujian Medical University, Fuzhou, China
🇨🇳
The Third People's Hospital affiliated to Fujian University of Chinese Medicine, Fuzhou, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy